Stockscreener 앱 받기
1.67
1.83%
0.03
전일 마감가:
$1.64
열려 있는:
$1.64
하루 거래량:
217.98K
Relative Volume:
0.38
시가총액:
$202.52M
수익:
-
순이익/손실:
$-19.57M
주가수익비율:
-0.5335
EPS:
-3.13
순현금흐름:
$-17.24M
1주 성능:
-1.76%
1개월 성능:
-0.60%
6개월 성능:
-2.34%
1년 성능:
-25.11%
1일 변동 폭
$1.64
$1.725
1주일 범위
$1.57
$1.725
52주 변동 폭
$1.33
$3.32
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
명칭
Inhibikase Therapeutics Inc
전화
(302) 295-3800
주소
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.67 | 198.88M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-21 | 개시 | BofA Securities | Buy |
| 2025-12-26 | 개시 | H.C. Wainwright | Buy |
| 2025-12-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
Does Inhibikase Therapeutics Inc. stock benefit from AI growthChart Signals & Free Expert Approved Momentum Trade Ideas - mfd.ru
Inhibikase Therapeutics (NASDAQ:IKT) Trading Up 6.9%Time to Buy? - MarketBeat
Aug Big Picture: Can Inhibikase Therapeutics Inc sustain its profitability2025 Valuation Update & Entry Point Confirmation Signals - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Pfizer (PFE) and Inhibikase Therapeutics (IKT) - The Globe and Mail
Aug Chart Watch: Is Inhibikase Therapeutics Inc a potential multi baggerJuly 2025 WrapUp & Target Return Focused Stock Picks - baoquankhu1.vn
Guidance Update: Is Precision Drilling Corporation affected by consumer sentimentEarnings Overview Summary & Weekly High Potential Alerts - baoquankhu1.vn
Risk Report: Does Inhibikase Therapeutics Inc stock benefit from AI growth2025 Market Outlook & Smart Investment Allocation Insights - baoquankhu1.vn
Market Outlook: Is HCA Healthcare Inc stock a smart retirement pickJuly 2025 Movers & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
What drives Inhibikase Therapeutics Inc.’s stock priceQuarterly Trade Report & Short-Term High Return Ideas - mfd.ru
B of A Securities Initiates Coverage of Inhibikase Therapeutics (IKT) with Buy Recommendation - Nasdaq
BofA Securities initiates coverage on Inhibikase stock with Buy rating By Investing.com - Investing.com South Africa
Inhibikase Therapeutics (NYSE:IKT) Earns Buy Rating from Analysts at Bank of America - MarketBeat
B of A Securities Initiates Coverage on IKT with 'Buy' Rating | - GuruFocus
BofA Securities initiates coverage on Inhibikase stock with Buy rating - Investing.com
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
What analyst consensus says on Inhibikase Therapeutics Inc. stockQuarterly Profit Report & Expert Curated Trade Ideas - Bollywood Helpline
Can Inhibikase Therapeutics Inc. stock sustain free cash flow growthMarket Growth Report & Daily Stock Momentum Reports - bollywoodhelpline.com
RSI Check: Does Inhibikase Therapeutics Inc outperform in volatile marketsMarket Growth Report & High Accuracy Investment Signals - baoquankhu1.vn
Inhibikase Therapeutics (NYSE:IKT) Trading Up 1.2%What's Next? - MarketBeat
Take Profit: Why Inhibikase Therapeutics Inc stock could outperform in 2025 - Bộ Nội Vụ
Published on: 2026-01-14 00:17:08 - Bộ Nội Vụ
How Inhibikase Therapeutics Inc IQT0 stock reacts to stronger dollarSwing Trade & Growth Focused Investment Plans - Bộ Nội Vụ
Why Inhibikase Therapeutics Inc. stock attracts global investorsBest Sellers Snapshot & trail grip notes for mixed terrain - Улправда
How Inhibikase Therapeutics Inc. stock performs in weak economyMarket Weekly Review & Technical Entry and Exit Tips - Улправда
Is Inhibikase Therapeutics Inc. stock attractive for passive investorsPortfolio Update Report & Weekly Watchlist of Top Performers - ulpravda.ru
Can Inhibikase Therapeutics Inc. stock sustain institutional interestJuly 2025 PostEarnings & Stepwise Trade Execution Plans - Улправда
How Inhibikase Therapeutics Inc. (IQT0) stock reacts to stronger dollarWeekly Loss Report & Safe Entry Point Identification - Улправда
Can Inhibikase Therapeutics Inc. (IQT0) stock surprise with quarterly results2025 Key Lessons & Low Drawdown Trading Strategies - Улправда
Published on: 2026-01-08 18:28:15 - ulpravda.ru
Inhibikase Halts Parkinson's Drug Development to Focus on PAH - MSN
Is Inhibikase Therapeutics Inc. stock attractive for income investorsHealthcare Stock Analysis & Budget Investment Success - Улправда
Laser Focus WorldInhibikase Therapeutics, Inc.Common Stock (Nasdaq:IKT) Stock Quote - FinancialContent
Dopamine Agonists Market is expected to reach US$ 1,732.41 - openPR.com
Inhibikase Therapeutics (NYSE:IKT) & Alpha Cognition (OTC:ACOGF) Head-To-Head Review - Defense World
Critical Survey: Liminatus Pharma (NASDAQ:LIMN) vs. Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
Comparing Liminatus Pharma (NASDAQ:LIMN) & Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
While Institutions Invested in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Benefited From Last Week's 24% Gain, Retail Investors Stood to Gain the Most - 富途牛牛
Inhibikase Therapeutics (NASDAQ:IKT) versus Liminatus Pharma (NASDAQ:LIMN) Head to Head Comparison - Defense World
Short Interest in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Rises By 29.0% - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) vs. Liminatus Pharma (NASDAQ:LIMN) Financial Survey - Defense World
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of “Buy” by Analysts - Defense World
Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path By Investing.com - Investing.com Nigeria
Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path - Investing.com Nigeria
Inhibikase Therapeutics (NASDAQ:IKT) Raised to “Strong-Buy” at HC Wainwright - Defense World
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) Raised to "Strong-Buy" at HC Wainwright - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Sell at Wall Street Zen - Defense World
Inhibikase Therapeutics (NYSE:IKT) Receives Buy Rating from HC Wainwright - MarketBeat
Inhibikase Therapeutics Inc (IKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):